Minimizing DILI risk in drug discovery — A screening tool for drug candidates
Simone Schadt(Roche (Switzerland)), Silke Simon(Roche (Switzerland)), Stefan Kustermann(Roche (Switzerland)), Franziska Boess(Roche (Switzerland)), C. McGinnis(Roche (Switzerland)), Andreas Brink(Roche (Switzerland)), R. Lieven(Roche (Switzerland)), Stephen Fowler(Roche (Switzerland)), Kuresh Youdim(Roche (Switzerland)), Mohammed Ullah(Roche (Switzerland)), Michaela Marschmann(Roche (Switzerland)), Christine Zihlmann(Roche (Switzerland)), Yves Siegrist(Roche (Switzerland)), Anne‐Christine Cascais(Roche (Switzerland)), Elisa Di Lenarda(Roche (Switzerland)), Evelyne Durr(Roche (Switzerland)), N Schaub(Roche (Switzerland)), Xiaoman Ang(Roche (Switzerland)), Volkmar Starke(Roche (Switzerland)), Thomas P. Singer(Roche (Switzerland)), Rubén Alvarez‐Sánchez(Roche (Switzerland)), Adrian Roth(Roche (Switzerland)), Franz Schuler(Roche (Switzerland)), Christoph Funk(Roche (Switzerland))
Cited by 88
Abstract
Related Papers
Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals
Harry M. Olson, Graham R. Betton, Denise E. Robinson et al.|Regulatory Toxicology and Pharmacology|2000|2k